Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized Phase 2/3 Study of DACOGEN (decitabine) plus JNJ-56022473 (talacotuzumab)
2015-001611-12Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of talacotuzumab in acute myeloid leukemia (AML) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Safety and recommended phase 2 dose (RP2D) of talacotuzumab monotherapy (Part A). Started Jun 2015; status: completed.
02
Drugs
talacotuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-001611-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001611-12.